Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANORAMIX PRODIGE 105 trial in metastatic pancreatic ductal adenocarcinoma
2024-517766-41-00Phase 2Authorised
- Sponsor
- GERCOR
- Start
- Feb 2026
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan, fluorouracil, oxaliplatin, gemcitabine, ciprofloxacin and 2 more in pancreatic adenocarcinoma (PDAC) (4 arms), sponsored by GERCOR. Primary endpoints: 6-month progression-free survival rate in Arm 1A and 6-month overall survival rate in Arm 2A. Planned start Feb 2026; status: authorised.
02
Drugs
irinotecanfluorouraciloxaliplatingemcitabineciprofloxacin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-517766-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517766-41-00.